About SemaLiving

SemaLiving is a patient-first education site for people prescribed, newly considering, or caring for someone using GLP-1 medications such as Ozempic, Wegovy, Zepbound, and Mounjaro.

We write for people managing real medical conditions — including type 2 diabetes, obesity-as-disease, cardiovascular risk, PCOS, prediabetes, fatty liver disease, sleep apnea, and metabolic syndrome — not for vanity weight-loss or self-directed medication use.

Editorial responsibility

SemaLiving is currently maintained by the SemaLiving Editorial Team with Lola/VSP Group as the human-of-record for corrections and publication decisions.

Publish gate: Before scaled traffic, SemaLiving should add a named licensed clinician reviewer with credential, bio, photo, and review cadence. Until then, no article should claim “medically reviewed.”

Our operating standard

• Use plain English and avoid unnecessary medical jargon.
• Prioritize patient safety, clinician conversations, source quality, and current verification over affiliate conversion.
• Disclose affiliate relationships clearly.
• Separate educational guidance from medical advice, diagnosis, or treatment.